China's Outsource Sales Model Takes A Big Step: SciClone Takes Out NovaMed
This article was originally published in PharmAsia News
Executive Summary
SciClone Pharmaceuticals will significantly broaden its commercial footprint across China by acquiring privately owned, Shanghai-based specialty pharma NovaMed Pharmaceuticals for close to $62 million plus potential earnouts in a deal that closed April 18
You may also be interested in...
Chinese Investor Consortium Buys SciClone But Relisting Possible
Against a background of positive changes to regulations and policies on pharmaceutical marketing in China, US-based SciClone has accepted a buyout offer from a consortium of Chinese investors, but may relist in China in the future.
Chi-Med’s Sinopharm Deal Opens Doors To China Market For Partners, CEO Says
The joint venture allows the newly formed subsidiary Hutchison Sinopharm to sell pharmaceuticals all over China and become a “super partner” for multinationals selling medicines in the country.
SciClone CEO Friedhelm Blobel On Building A Specialty Pharma Business In China: An Interview With PharmAsia News (Part 2 of 2)
On the sidelines of the annual JP Morgan Healthcare Conference, Blobel talks about China price cuts, FCPA compliance, renegotiating promotional contracts with Sanofi, Pfizer and Baxter, and SciClone’s plans for in-licensing the next Zadaxin.